Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Protagonist Therapeutics, Inc.

Market Cap 7.26B 6.33B 5.86B 5.49B 10.29B 685B 10.35B 69.53B 26.95B 337B 27.25B 26.66B 1,171B P/E 2026 *
28.9x
P/E 2027 * -93.8x
Enterprise Value 6.68B 5.83B 5.4B 5.05B 9.48B 631B 9.53B 64.03B 24.82B 310B 25.09B 24.55B 1,078B EV / Sales 2026 *
13.1x
EV / Sales 2027 * 41.9x
Free-Float
97.28%
Yield 2026 *
-
Yield 2027 * -
1 day+1.27%
1 week+2.81%
Current month+13.36%
1 month+10.64%
3 months+14.15%
6 months+31.16%
Current year+29.22%
1 week 108.53
Extreme 108.53
114.48
1 month 92.75
Extreme 92.75
114.48
Current year 77
Extreme 77
114.48
1 year 49.38
Extreme 49.38
114.48
3 years 13.72
Extreme 13.72
114.48
5 years 6.91
Extreme 6.91
114.48
10 years 4.47
Extreme 4.47
114.48
Manager TitleAgeSince
Chief Executive Officer 69 2008-11-30
Director of Finance/CFO 52 2022-04-17
Chief Tech/Sci/R&D Officer - 2026-03-31
Director TitleAgeSince
Director/Board Member 69 2008-11-30
Chairman 71 2014-03-18
Director/Board Member 69 2016-06-30
Date Insider Type Main position Quantity % Market Cap.
06-09Fiscal year

Director

27,000 0.0420%
05-28Fiscal year

Director

27,000 0.0420%
05-11Fiscal year

Chief Executive Officer

225,000 0.3526%
Change 5-day change 1-year change 3-year change Capi.($)
+1.27%+2.81%+111.59%+310.25% 7.26B
+1.44%+1.71%-10.98%-5.59% 43.13B
+3.31%+5.93%+310.97%+532.23% 34.65B
+2.84%+2.14%+9.34%+45.55% 30.03B
-1.70%-7.54%+8.43%-21.54% 28B
-1.90%-1.56%+10.24%+22.81% 24.45B
-0.14%+5.86% - - 14.34B
+0.68%-1.53%+48.76%+108.76% 13.14B
-0.57%-2.43%+5.08%+6.76% 12.53B
-0.26%+1.15%+98.13%+79.60% 12.25B
Average +0.50%+0.94%+65.73%+119.87% 21.98B
Weighted average by Cap. +0.79%+1.32%+67.10%+118.11%

Financials

2026 *2027 *
Net sales 509M 444M 411M 385M 722M 48.05B 726M 4.88B 1.89B 23.65B 1.91B 1.87B 82.12B 160M 139M 129M 121M 227M 15.08B 228M 1.53B 593M 7.42B 600M 587M 25.77B
Net income 258M 225M 208M 195M 366M 24.36B 368M 2.47B 958M 11.99B 969M 948M 41.63B -87.49M -76.28M -70.65M -66.14M -124M -8.26B -125M -838M -325M -4.06B -328M -321M -14.11B
Net Debt -574M -500M -463M -434M -814M -54.15B -819M -5.5B -2.13B -26.66B -2.15B -2.11B -92.56B -565M -492M -456M -427M -801M -53.29B -805M -5.41B -2.1B -26.23B -2.12B -2.07B -91.07B
Logo Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. is a biopharmaceutical company with a technology platform that enables de novo discovery of peptide therapeutics. The Company's programs fall into three therapeutic areas: inflammation and immunology (I&I), hematology, and metabolic diseases. Its clinical and pre-clinical programs address biologically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, obesity dual agonist peptide PN-458, oral small molecule hepcidin functional mimetic PN-8047, and IL-4 and amylin programs. The ICOTYDE (icotrokinra) is used for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. Rusfertide is an investigational injectable mimetic of the natural hormone hepcidin in development for the treatment of the rare blood disorder polycythemia vera (PV).
Employees
131
Date Price Change Volume
26-06-18 112.86 $ +1.27% 1,533,672
26-06-17 111.44 $ +0.72% 742,534
26-06-16 110.64 $ -1.62% 504,794
26-06-15 112.46 $ +2.44% 536,301
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
112.86USD
Average target price
118.69USD
Spread / Average Target
+5.17%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTGX Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!